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A B S T R A C T
Dystrophinopathies are multi-system disorders that affect the skeletal musculature, the cardio-respiratory system
and the central nervous system. The systematic screening of suitable biofluids for released or altered proteins
promises new insights into the highly complex pathophysiology of X-linked muscular dystrophy. However,
standard detection approaches using antibody-based assays often fail to reproducibly detect low-abundance
protein isoforms in dilute biological fluids. In contrast, mass spectrometric screening approaches enable the
proteome-wide identification of minor protein changes in biofluids. This report describes the findings from the
comparative proteomic analysis of whole saliva samples from wild type versus the established mdx-4cv mouse
model of highly progressive muscular dystrophy, focusing on the kallikrein protein family. Kallikrein-1 (Klk1)
and 13 Klk1-related peptidases were identified in saliva and serum from normal mice. Comparative proteomics
revealed elevated saliva levels of the Klk1-related peptidases Klk1-b1, Klk1-b5 and Klk-b22, as well as an in-
creased Klk-1 concentration, which agrees with higher Klk-1 levels in serum from mdx-4cv mice. This indicates
altered cellular signaling, extracellular matrix remodeling and an altered immune response in the mdx-4cv
mouse, and establishes liquid biopsy procedures as suitable bioanalytical tools for the systematic survey of
complex pathobiochemical changes in animal models of muscular dystrophy.
1. Introduction
The systematic identification of pathobiochemical changes in pro-
teins is the focus of quantitative body fluid proteomics, aiming at both
the improved understanding of alterations in local versus multi-system
disease processes and the discovery of proteome-wide changes [1]. If
distinct alterations in the protein composition of biological fluids, such
as blood, cerebrospinal fluid, bronchoalveolar lavage fluid, saliva, tears,
sweat or urine, mirror disease-related alterations, then these body fluids
present an excellent starting point for the in-depth analysis of complex
pathophysiological processes. Although the plasma/serum and urine
proteomes represent well established sources for the discovery of new
disease markers [2–4], the existence of a small number of highly
abundant protein species and the extensive dynamic range of proteins
in these biofluids present challenging analytical obstacles [5]. The 15
most abundant proteins in urine and plasma account for approximately
60% and 90% of the total biofluid proteome, respectively [6,7]. In
contrast, this class of highly abundant proteins makes up only ap-
proximately 30% of the total saliva protein complement, as recently
confirmed by the advanced mass spectrometric cataloguing of the
human saliva proteome [8].
The saliva proteome is primarily composed of protein species de-
rived from the oral cavity, but also infiltrating molecules from plasma.
This includes many protein species with a considerable diagnostic,
prognostic or disease/therapy-monitoring potential, such as enzymes,
cytokines, hormones and circulating protein factors [9]. Hence, ana-
lyzing the protein constituents of saliva offers potentially a compre-
hensive insight into both local and systemic changes due to physiolo-
gical adaptations or pathological insults [10]. Saliva diagnostics is
already established for the evaluation of oral diseases, including the
detection of dental caries, gingivitis and periodontal diseases, and the
autoimmune Sjogren's syndrome that is characterized by salivary and
lacrimal gland dysfunction, as well as oral cancer and certain types of
head and neck cancer [11]. In addition, circulating marker proteins
found in saliva have the potential to be also useful for the clinical
evaluation of common systemic diseases, such as diabetes mellitus,
cardiovascular disorders, cancers of the pancreas, breast, lungs or
prostate, infectious diseases, renal abnormalities and neurological dis-
orders [12].
In this report, the proteomic characterization of saliva has been
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extended to studying the mdx-4cv mouse model of the most frequently
inherited neuromuscular disorder of early childhood, Duchenne mus-
cular dystrophy [13]. Primary abnormalities in the Dmd gene cause the
almost complete absence of the membrane cytoskeletal protein dys-
trophin in skeletal muscle tissues and result in the collapse of the sar-
colemmal dystrophin-associated glycoprotein complex [14]. Loss of
membrane integrity in dystrophin-deficient muscles triggers a complex
pathogenesis that is characterized by abnormal excitation-contraction
coupling, impaired ion homeostasis, fibre degeneration, reactive myo-
fibrosis and sterile inflammation [15–17]. Subtypes of skeletal muscles
are differentially affected in dystrophinopathies. Muscle wasting causes
initially proximal lower limb and truncal weakness, which is followed
by the progressive degeneration of upper limb and distal muscles [18].
In addition to the affected skeletal musculature, secondary complica-
tions occur in the respiratory system, the heart and the central nervous
system of Duchenne patients [19,20].
Saliva proteomics was carried out with samples from the established
mdx-4cv mouse model of dystrophinopathy [21], which exhibits char-
acteristic proteome-wide abnormalities in the skeletal musculature,
heart and brain [22–24]. Proteomic findings were compared to results
from the recent mass spectrometric profiling of mdx-4cv serum [25] and
revealed significantly elevated levels of kallikrein-1 and kallikrein-re-
lated peptidases [26]. The kallikrein/kinin and bradykinin signaling
axis of vasoactive peptides is involved in blood pressure regulation,
tissue homeostasis and renal function. In addition, the endogenous
kallikrein/kinin system was shown to be involved in various neurolo-
gical diseases [27] and appears to play a protective role in dystrophic
mdx muscle [28]. Building on these findings and the recent proteomic
identification of greatly reduced levels of the kallikrein-1 related pep-
tidase Klk1-b9 in mdx muscle [29], it was of interest to study the status
of kallikreins in mdx-4cv saliva specimens. The establishment of ele-
vated saliva kallikrein-1 and kallikrein-related peptidases, shown in this
report using comparative proteomics, may be related to altered cellular
signaling, remodeling of the extracellular matrix and an altered im-
mune response in the mdx-4cv mouse model of dystrophinopathy.
2. Materials and methods
2.1. Materials
The general analytical grade reagents and materials used in this
study were sourced from GE Healthcare (Little Chalfont,
Buckinghamshire, UK), BioRad Laboratories (Hemel-Hempstead,
Hertfordshire, UK) and Sigma Chemical Company (Dorset, UK).
Ultrapure acrylamide stock solutions were purchased from National
Diagnostics (Atlanta, GA, USA), sequencing grade modified trypsin was
obtained from Promega (Madison, WI, USA) and protease inhibitors
were purchased from Roche Diagnostics (Mannheim, Germany). For the
filter-aided sample preparation method FASP, Vivacon 500 with 30 kDa
molecular mass cut-off spin filters were acquired from Sartorius
(Göttingen, Germany).
2.2. Saliva samples from the mdx-4cv mouse model of Duchenne muscular
dystrophy
The mdx-4cv mouse is a mutant variant of the spontaneous mdx
model of Duchenne muscular dystrophy that has been generated by
chemical mutagenesis [30]. For the proteomic profiling of biofluids,
saliva samples were obtained from 6-month-old control C57BL/6 mice
and age-matched mdx-4cv mice through the Bioresource Unit of the
University of Bonn [22], where mice were kept under standard condi-
tions according to German legislation on the use of animals in experi-
mental research. A small crystal of Vitamin C was carefully placed in
the mouth of mice immediately post mortem, thereby inducing a sali-
vating reflex. The produced saliva was suctioned off with a micro
pipette and the oral cavity irrigated with 10μl of phosphate-buffered
saline. The collected saliva was then immediately placed in liquid ni-
trogen. Samples were transported to Maynooth University on dry ice in
accordance with the Department of Agriculture (animal by-product
register number 2016/16 to the Department of Biology, National Uni-
versity of Ireland, Maynooth) and stored at − 80 °C prior to analysis. To
minimize degradation of salivary proteins, protease inhibitor cocktails
[24] were added to individual samples from wild type and mdx-4 cv
mice.
2.3. Proteolytic digestion of salivary proteins
The protein concentration of saliva samples was equalized with
label-free solubilisation buffer (6M urea, 2M thiourea, 10mM Tris, pH
8.0 in LC-MS grade water), and 30 µg of protein was processed by the
filter-aided sample preparation (FASP) method, as described in detail
by Wiśniewski et al. [31], using a trypsin to protein ratio of 1:25
(protease:protein). Following overnight digestion and elution of pep-
tides from the spin filter, 2% trifluoroacetic acid (TFA) in 20% acet-
onitrile (ACN) was added to the filtrates (3:1 (v/v) dilution). The
peptides were then purified using Pierce C18 spin columns from
Thermo Fisher Scientific (Dublin, Ireland), dried through vacuum
centrifugation and re-suspended in mass spectrometry loading buffer
(2% ACN, 0.05% TFA in LC-MS grade water). Peptides were vortexed,
sonicated and briefly centrifuged at 14,000×g and the supernatant
transferred to mass spectrometry vials for label-free liquid chromato-
graphy mass spectrometry (LC-MS/MS).
2.4. Label-free liquid chromatography mass spectrometry
The LC-MS/MS analysis of salivary peptides was performed using an
Ultimate 3000 NanoLC system (Dionex Corporation, Sunnyvale, CA,
USA) coupled to a Q-Exactive mass spectrometer (Thermo Fisher
Scientific). 800 ng of each digested sample was loaded by an auto-
sampler onto a C18 trap column (C18 PepMap, 300 µm id×5mm,
5 µm particle size, 100 Å pore size; Thermo Fisher Scientific). The trap
column was switched on-line with an analytical Biobasic C18 Picofrit
column (C18 PepMap, 75 µm id × 50 cm, 2 µm particle size, 100 Å pore
size; Dionex). Peptides were eluted over a 65-min binary gradient
[solvent A: 2% (v/v) ACN and 0.1% (v/v) formic acid in LC-MS grade
water and solvent B: 80% (v/v) ACN and 0.1% (v/v) formic acid in LC-
MS grade water]: 3% solvent B for 5min, 3–10% solvent B for 5min,
10–40% solvent B for 30min, 40–90% solvent B for 5min, 90% solvent
B for 5min and 3% solvent B for 10min [32]. The column flow rate was
set to 0.3 µL/min. Data were acquired with Xcalibur software (Thermo
Fisher Scientific). The mass spectrometer was externally calibrated and
operated in positive, data-dependent mode. A full survey MS scan was
performed in the 300–1700m/z range with a resolution of 140,000 (m/
z 200) and a lock mass of 445.12003. Collision-induced dissociation
(CID) fragmentation was carried out with the fifteen most intense ions
per scan and at 17,500 resolution. Within 30 s a dynamic exclusion
window was applied. An isolation window of 2m/z and one microscan
were used to collect suitable tandem mass spectra.
2.5. Protein identification and quantification
Proteins present in the wild type and the mdx-4cv salivary pro-
teomes were initially identified using Proteome Discoverer 1.4 against
Sequest HT (SEQUEST HT algorithm, licence Thermo Scientific, regis-
tered trademark University of Washington, USA) using the UniProtKB/
Swiss-Prot database, with 25,041 sequences for Mus musculus. The fol-
lowing search parameters were used for protein identification: (i)
peptide mass tolerance set to 10 ppm, (ii) MS/MS mass tolerance set to
0.02 Da, (iii) an allowance of up to two missed cleavages, (iv) carba-
midomethylation set as a fixed modification and (v) methionine oxi-
dation set as a variable modification [32]. Peptides were filtered using a
minimum XCorr score of 1.5 for 1, 2.0 for 2, 2.25 for 3 and 2.5 for 4
S. Murphy, et al. Biochemistry and Biophysics Reports 18 (2019) 100541
2
charge states, with peptide probability set to high confidence. XCorr is a
search-dependent score employed by the SEQUEST HT search engine in
Proteome Discoverer, and reflects the number of fragment ions that are
common to two different peptides with the same precursor mass. Since
the XCorr value is dependent upon the number of identified fragment
ions, its value is usually higher for larger peptides. XCorr scores are
filtered based on charge state, whereby larger XCorr thresholds are used
for higher charge states. For quantitative analysis, samples were eval-
uated with MaxQuant software (version 1.6.1.0) and the Andromeda
search engine used to explore the detected features against the Uni-
ProtKB/SwissProt database for Mus musculus. The following search
parameters were used: i) first search peptide tolerance of 20 ppm, ii)
main search peptide tolerance of 4.5 ppm, iii) cysteine carbamido-
methylation set as a fixed modification, iv) methionine oxidation set as
a variable modification, v) a maximum of two missed cleavage sites and
vi) a minimum peptide length of seven amino acids. The false discovery
rate (FDR) was set to 1% for both peptides and proteins using a target-
decoy approach [8]. Relative quantification was performed using the
MaxLFQ algorithm [33]. The “proteinGroups.txt” file produced by
MaxQuant was further analyzed in Perseus (version 1.5.1.6). Proteins
that matched to the reverse database or a contaminants database or that
were only identified by site were removed. The LFQ intensities were
log2 transformed, and only proteins found in all eight replicates in at
least one group were used for further analysis. Data imputation was
performed to replace missing values with values that simulate signals
from peptides with low abundance chosen from a normal distribution
specified by a downshift of 1.8 times the mean standard deviation of all
measured values and a width of 0.3 times this standard deviation [34].
A two-sample t-test was performed using p < 0.05 on the post im-
putated data to identify statistically significant differentially abundant
proteins.
3. Results and discussion
3.1. Proteomic identification of kallikrein isoform Klk1 and Klk1-related
peptidases in saliva and serum
The recent proteomic survey of the mdx mouse model of dystro-
phinopathy confirmed that the dystrophin isoform Dp427-M represents
the most reduced protein species in the dystrophic quadriceps femoris
muscle and established the kallikrein-1 (Klk1) related peptidase Klk1-
b9 as the second most reduced muscle-associated protein [29]. In ad-
dition, proteomic profiling of the dystrophic mdx-4cv mouse revealed
increased Klk1 levels in serum [25]. Based on these findings, it was of
interest to evaluate the presence of kallikreins and related peptidases in
normal saliva, as compared to more widely researched serum samples
[4], and investigate potential changes in saliva from dystrophic rodents.
As listed in Table 1, Klk1 and 13 Klk1-related peptidases, i.e. isoforms
b1, b3, b4, b5, b8, b9, b11, b16, b21, b22, b24, b26 and b27 [26], were
identified by mass spectrometry in both saliva and serum from normal
mice. The mass spectrometrically identified total saliva protein popu-
lation and the differential presence of protein species in saliva versus
serum samples are listed in the accompanying Data-in-Brief publication
[35].
3.2. Comparative proteomic profiling of kallikrein-1 and Klk1-related
peptidases in saliva from the mdx-4cv mouse model of dystrophinopathy
Following the proteomic cataloguing of Klk1 and related peptidases
in wild type saliva, whole saliva samples from normal versus the es-
tablished mdx-4cv mouse model of highly progressive X-linked mus-
cular dystrophy were analyzed by mass spectrometry. Fig. 1 gives an
overview of the proteomic workflow and the number of biological and
technical repeats used in this comparative study, as well as a summary
of the main findings with a focus on altered kallikreins. The re-
presentative silver-stained gel of whole saliva specimens shows a
relatively comparable expression pattern of proteins in wild type versus
mdx-4cv samples with only a few differences in the intensity of in-
dividual protein bands (Fig. 1). The mass spectrometric identification of
Klk1 of apparent 28.8 kDa, which apparent protein band is marked in
the SDS-PAGE gel at the approximate 30 kDa region (Fig. 1), estab-
lished its presence in mdx-4cv saliva with a 37% sequence coverage
with 13 peptides and 3 unique peptides (Fig. 2A). Representative MS/
MS scans are shown for the unique peptide NNFLEDEPSAQHR that was
used to identify the Klk-1 isoform in both wild type and mdx-4cv
samples, which illustrates higher intensities of peaks from mdx-4cv
peptides compared to wild type peptides (Fig. 2B, C). Additional MS/
MS scans of unique peptides used to identify kallikrein are provided in
the accompanying Data in Brief article [35].
As listed in Table 2, comparative proteomics revealed elevated
saliva levels of the Klk1-related peptidases Klk1-b1, Klk1-b5 and Klk-
b22, as well as an increased Klk-1 concentration, which agrees with
higher Klk-1 levels in serum from mdx-4cv mice [25]. In addition, ga-
lectin-3-binding protein, lysosomal alpha-mannosidase and beta-nerve
growth factor were found to be increased in mdx-4cv saliva. Mass
spectrometric analysis identified a reduced concentration for adenosine
deaminase, odorant-binding protein 2a, elongation factor-1 (alpha 1
and 2), type II keratin (cytoskeletal 1), ovostatin, chitinase-like protein
4 and the BPI fold-containing family A member 2 in mdx-4cv saliva
(Table 2). Fig. 3 shows a volcano plot of all identified proteins based on
relative abundance differences between wild type and mdx-4cv saliva,
illustrating the distribution of quantified proteins according to p-value
and fold change.
Kallikreins have a great potential as general markers of degen-
erative processes [36] and have previously been identified in saliva by
various proteomic approaches [37]. Kallikreins of approximately
30 kDa appear to be relatively abundant protein species within the
saliva proteome and are stable constituents of this body fluid. Thus,
although proteins are only minor components of watery saliva [10], the
kallikreins can be readily identified by sensitive biochemical metho-
dology in dilute saliva samples. This establishes kallikreins as potential
biomarker candidates of secondary changes due to dystrophin defi-
ciency in the mdx-4cv mouse model of Duchenne muscular dystrophy.
However, an important modulating factor to take into account is the
potential effect of prednisolone treatment on kallikrein levels. Gene
expression profiles of prednisolone-treated mdx mice showed a delayed
over-expression of genes encoding kallikreins 13, 16 and 26 [38]. Based
on the initial proteomic identification of saliva kallikreins as new bio-
marker candidates, as reported here, it will be crucial to carry out a
more detailed characterization of potential confounding factors in fu-
ture analyses. This would include the evaluation of possible influences
of saliva kallikrein levels due to general life style issues, physical ac-
tivity, emotional stress, disease-unrelated neuromuscular trauma, in-
flammation, metabolic abnormalities, co-morbidities such as cardio-
myopathic complications in dystrophinopathy, diet, pharmacological
side effects and/or surgical procedures, as discussed below.
At the level of pathophysiological mechanisms, elevated levels of
circulating kallikrein isoform Klk-1 and Klk1-related peptidases suggest
altered cellular signaling at the level of the kallikrein-kinin system and
the regulation of tissue homeostasis [28], as well as remodeling of the
extracellular matrix and a modification of the immune response in X-
linked muscular dystrophy [39]. Thus, comparative saliva proteomics is
capable of establishing distinct changes in the biofluid protein com-
plement and this study confirmed that liquid biopsy procedures are
suitable bioanalytical tools for the systematic survey of complex pa-
thobiochemical changes in muscular dystrophy [4].
3.3. Saliva as a suitable biofluid for non-invasive and systemic sampling
approaches in neuromuscular pathology
Routine clinical biofluid analyses in the field of muscle pathology
are usually restricted to simple blood tests with a focus on muscle-
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derived serum proteins that are indicative of skeletal muscle damage,
including creatine kinase, myoglobin, alanine aminotransferase, as-
partate aminotransferase and a variety of glycolytic enzymes [40].
However, in the case of childhood disorders of the neuromuscular
system, these serum markers are relatively non-specific and potentially
susceptible to (i) modifying effects due to co-morbidities, (ii) con-
siderable age-related changes during childhood development, (iii)
fluctuations during disease progression, (iv) obscuring influences of
patient gender and ethnicity, (v) prone to changes due to general life
style, nutritional status, metabolic imbalances and physical activity
levels, (vi) modifying effects of intramuscular injections, surgery or
drug treatments, and (vii) seasonal variations in concentration levels
[4]. Taken into account the above listed issues with existing diagnostic
markers of muscle damage in a disease of early childhood, the findings
reported here are of considerable bioanalytical interest and establish
whole saliva samples as a suitable source for the establishment of
superior biomarker signatures [41].
Importantly, the more evenly distributed concentration range of
saliva-associated protein species, as compared to serum/plasma and
urine, allows the routine usage of whole saliva specimens without the
need for elaborative pre-fractionation steps in large-scale proteomic
surveys [8–10]. This establishes the saliva proteome as an ideal non-
invasive and systemic sampling measure for the discovery of proteome-
wide changes. Whole saliva is a highly complex mixture of fluids, which
are crucial for the physiological functioning, preservation and main-
tenance of tissues in the oral cavity. Saliva derives mostly from the
secretory activities of salivary glands, including the major sub-
mandibular, paratoid and sublingual glands and the minor labial, pa-
latine, lingual and buccal glands [42]. Kallikrein, which acts as an
enzyme that converts kininogen to the vasodilator bradykinin, is se-
creted by the acinar cells of major salivary glands. However, salivary
glands exhibit a high permeability for their surrounding capillaries,
Table 1
Mass spectrometric identification of kallikrein-1 and kallikrein-related peptidases in mouse saliva and serum.
Accession Number Protein Name Number of unique peptides in
saliva
% Sequence coverage in
saliva
Number of unique peptides in
serum
% Sequence coverage in
serum
P15947 Kallikrein-1 (Klk1) 2 27.59 3 38.7
P00755 Klk1-related peptidase b1 4 41.76 10 72.8
P00756 Klk1-related peptidase b3 4 39.46 8 77.01
P00757 Klk1-related peptidase b4 6 33.98 10 43.75
P15945 Klk1-related peptidase b5 4 30.27 6 47.51
P07628 Klk1-related peptidase b8 7 49.43 8 70.5
P15949 Klk1-related peptidase b9 5 45.98 10 68.97
P15946 Klk1-related peptidase
b11
5 44.83 13 73.56
P04071 Klk1-related peptidase
b16
7 44.83 9 60.92
Q61759 Klk1-related peptidase
b21
2 37.55 2 49.43
P15948 Klk1-related peptidase
b22
5 27.03 13 71.81
Q61754 Klk1-related peptidase
b24
3 38.4 4 42.59
P36369 Klk1-related peptidase
b26
3 42.53 5 57.47
Q9JM71 Klk1-related peptidase
b27
3 41.83 6 58.17
Fig. 1. Comparative proteomic profiling of
kallikrein and related peptidases in saliva from
the mdx-4cv model of Duchenne muscular
dystrophy. Shown is the bioanalytical work-
flow and major findings of the mass spectro-
metric characterization of changes in kallik-
rein-1 and related peptidases. A representative
silver-stained protein gel of whole saliva sam-
ples from wild type versus dystrophic mice is
shown. The relative position of the approx-
imate 30 kDa Klk-1 band is marked by an ar-
rowhead. Molecular mass standards are in-
dicated on the left of the gel.
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which allows the infiltration of circulating peptides and proteins from
blood. The proteomic comparison of wild type saliva and wild type
serum revealed a 57% commonality in protein species. Thus, saliva
kallikreins might originate to a large extent from blood and this might
explain the similar changes of Klk1 in blood and saliva of the mdx-4cv
mouse model of dystrophinopathy, as established here by proteomic
analysis.
3.4. Biofluid markers of the molecular pathogenesis of muscular dystrophy
The newly established increase in kallikreins in both saliva and
serum from the dystrophic mdx-4cv mouse is an appropriate addition to
the list of already established biofluid marker candidates of X-linked
muscular dystrophy. Biofluid marker research has mostly focused on
the effects of dystrophin deficiency on plasma/serum specimens and
urine [4]. A change of abundance in a great variety of muscle-derived
proteins, mostly related to fibre degeneration, cellular stress and fi-
brosis, and non-muscle markers of secondary pathological processes,
such as sterile inflammation, has been identified by mass spectrometric
analysis [43]. This includes proteins or protein fragments of muscle
components derived from the sarcomere, the membrane cytoskeleton,
the non-sarcomeric cytoskeletal network, the extracellular matrix and
Fig. 2. Proteomic identification of kallikrein
isoform Klk1 in saliva from the mdx-4cv mouse
model of Duchenne muscular dystrophy. (A)
Shown is the sequence coverage of kallikrein
as determined by LC-MS/MS analysis. Unique
peptide sequences are underlined and all
identified peptide regions are shown in bold.
Panels (B) and (C) show representative MS/MS
scans of the unique Klk-1 peptide NNFLEDEP-
SAQHR, which was identified and compared in
wild type versus mdx-4cv saliva, respectively.
Table 2
List of proteins with an altered abundance in whole saliva samples from the mdx-4cvmouse model of Duchenne muscular dystrophy as revealed by comparative mass
spectrometry-based proteomics.
Protein ID Protein Name Gene Name Number of peptides Number of unique peptides p-value Fold change Score
P15947 Kallikrein-1 Klk1 13 3 0.008229 4.16 189.7
Q07797 Galectin-3-binding protein Lgals3bp 4 4 0.000788 3.54 33.4
O09159 Lysosomal alpha-mannosidase Man2b1 21 21 0.001934 3.36 323.3
P15948 Kallikrein 1-related peptidase b22 Klk1b22 14 9 0.010188 1.97 323.3
P00755 Kallikrein 1-related peptidase b1 Klk1b1 14 6 0.006031 1.96 215.4
P15945 Kallikrein 1-related peptidase b5 Klk1b5 13 5 0.031962 1.49 323.3
P01139 Beta-nerve growth factor Ngf 4 4 0.018827 1.34 323.3
P03958 Adenosine deaminase Ada 4 4 0.017819 0.44 56.6
Q8K1H9 Odorant-binding protein 2a Obp2a 3 3 0.045699 0.42 75.9
P10126;P62631 Elongation factor-1, Eef1a1 7 7 0.013068 0.41 100.4
alpha 1 and 2 Eef1a2
P04104 Keratin, type II, cytoskeletal 1 Krt1 10 5 0.039762 0.37 323.3
Q3UU35 Ovostatin homolog Ovos 6 6 0.000347 0.34 323.3
Q91Z98 Chitinase-like protein 4 Chil4 7 7 0.003153 0.15 95.2
P07743 BPI fold-containing family A member 2 Bpifa2 6 6 0.007214 0.11 289.8
Fig. 3. Volcano plot of all identified proteins based on relative abundance
differences between wild-type and mdx-4cv saliva. The volcano plot illustrates
the distribution of quantified saliva proteins according to p-value (-log10 p-
value) and fold change (log2 mean LFQ intensity difference). Grey and black
boxes represent individual protein species that were identified to exhibit a
statistically significant (p-value < 0.05) decrease or increase in their abun-
dance in mdx-4cv saliva, respectively. All protein-presenting boxes above the
line are those which also passed an FDR criteria of 0.05.
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major classes of organelles, such as the sarcolemma, the sarcoplasmic
reticulum and mitochondria. These changes in the biofluid proteome
reflect complex pathophysiological alterations due to progressive cel-
lular degeneration and enhanced surface membrane rupturing. Ab-
normal Ca2+-handling at the level of the plasma membrane, cytosol
and sarcoplasmic reticulum results in increased Ca2+-fluxes through
the sarcolemma, elevated Ca2+-levels in the sarcosol and impaired lu-
minal Ca2+-buffering, which triggers enhanced fibre proteolysis and
skeletal muscle necrosis [17]. These major pathophysiological changes
appear to be associated with considerable fluctuations in the protein
constituents of biofluids.
Since the signaling axes of kallikreins and members of the matrix
metalloproteinase family were shown to intersect and this may influ-
ence metalloproteinase function in the extracellular matrix under con-
ditions of pathological dysregulation [44], kallikreins might be in-
volved in the modification of the extracellular matrix [39]. In
dystrophin-deficient muscle, significant increases in various collagens
and the matricellular protein periostin [45], as well as the extracellular
matrix proteins asporin, decorin, dermatopontin and prolargin [46], are
typical features of reactive myofibrosis and contractile tissue damage
[16]. Thus, kallikreins might act as modulating factors in the deposition
of these myofibrotic protein aggregates in the mdx-4cv mouse. The re-
cent proteomic profiling of highly purified sarcolemma vesicles from
mdx-4cv muscle indicates the up-regulation of proteins involved in
immune cell infiltration [47], which agrees with a robust inflammatory
response by the innate immune system due to chronic skeletal muscle
damage [48]. This process might also involve kallikreins that were
previously shown to assist in immune invasion processes [39].
4. Conclusions
Using comparative proteomic profiling, elevated Klk1 levels were
identified in both saliva and serum, suggesting that these biofluids are
suitable for testing new disease marker candidates in animal models of
progressive muscular dystrophy. Changes in kallikreins appear to be
appropriate diagnostic targets, since these proteins are easily assessable
by non-invasive or minimally invasive sampling procedures. Saliva Klk1
should therefore be considered a potential biomarker candidate for
studying the mdx-4cv mouse model of dystrophinopathy, which might
be suitable to establish a highly sensitive and robust assay system that is
applicable for repeated diagnostic procedures. Changes in kallikrein
concentration should be convenient for the development of a cost-ef-
fective assay system that is relatively specific for disease status and
progression, and should not be prone to sampling errors. Solid bio-
markers are especially needed for the improved monitoring of experi-
mental therapeutic approaches during pre-clinical and clinical testing
[49]. Considerable advances have been made over the last few years in
the development of standardized saliva collection devices [50], there-
fore it should be relatively easy to apply saliva-based biomarker tests to
the field of muscular dystrophy diagnostics.
Novel biomarker candidates, such as kallikreins, might be useful to
evaluate new pharmacological substances that target ion homeostasis,
muscle growth, fibre regeneration, blood flow, the cellular stress re-
sponse, energy metabolism and/or myofibrosis, as well as the in-
flammatory response and oxidative stress in muscular dystrophy. A
superior biomarker signature of dystrophic changes, as mirrored by
proteome-wide changes in easily assessable biofluids, would also be
beneficial for the routine evaluation of advanced therapeutic ap-
proaches, such as stem cell treatment, myoblast transfer, gene transfer,
exon skipping, stop codon read-through, utrophin replacement and
CRISPR/Cas9 genome editing. In the long-term, based on this type of
applied muscular dystrophy research, newly characterized biomarkers
can then hopefully be tested for their effectiveness to improve the di-
agnosis, prognosis and therapy monitoring of patients suffering from
dystrophinopathy.
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